Clinical trial Recruiting at 3 sites Observational Ages 16 and up

Hepatitis D in people with chronic hepatitis B in Vietnam

Official title: Hepatitis Delta Virus Infection: Cross-sectional Study in Patients With Chronic Hepatitis B Virus Infection

Run by Tam Anh Research Institute · NCT06638320 · Data updated 2026-11-12

This observational study tests how common hepatitis D is among people with chronic hepatitis B and looks at the types of HDV and related factors.

More Chronic Hepatitis B trials

Quick facts

Study typeObservational
Ages16 Years and up
SexAll
Enrollment2452 (estimated)
SponsorTam Anh Research Institute
Academic / other
Locations3 sites (Hà Nội, Northern Vietnam and 2 other locations)
StatusRecruiting
StartedNovember 1, 2024
Main results expectedNovember 30, 2026
Study endsDecember 30, 2026
Registry record updatedOctober 2, 2026
Trial IDNCT06638320 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults and adolescents aged 16 and older with chronic hepatitis B (HBsAg positive for at least six months, or HBsAg positive with total anti-HBc positive and IgM anti-HBc negative) who are patients or inpatients at the participating centers.

Probably not a fit

Participants who do not have chronic hepatitis B or who do not consent may not benefit from findings or testing beyond standard care.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This cross-sectional study enrolls patients with chronic hepatitis B from several hospitals in Vietnam to measure HDV prevalence and genotype distribution. Researchers collect questionnaire data on epidemiologic risk factors and obtain a blood sample for testing. The study aims to identify factors related to HDV infection, including vaccination history, drug use, family and environmental factors, and lifestyle. Only individuals who consent and meet the HBV criteria are eligible to participate, and data collection occurs at multiple hospital sites. No experimental interventions are planned; the study is purely observational.

Why it matters

Potential benefit: If successful, the study could improve understanding of HDV burden among HBV patients and guide screening and public health strategies.

How similar studies have gone: Previous research has shown HDV can be prevalent among HBV patients in some regions, supporting the value of region-specific prevalence data.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients ≥ 16 years old undergo testing at the Testing Center of Tam Anh General Hospital or Tam Anh TP. Ho Chi Minh General Hospital, with chronic hepatitis B HBsAg (+) standards for six months or over or HBsAg (+) combined with HBcAb total (+) and HBcAb-immunoglobulin M (-).
* Patients ≥ 16 years old with chronic hepatitis B come to be examined or are inpatients at the Gastroenterology - Hepatobiliary Center of Bach Mai Hospital, diagnosed with hepatocellular carcinoma, and cirrhosis

Exclusion Criteria:

* Patients do not agree to participate in the study or refuse to sign a written informed consent.

Where it's running

  • Bach Mai General Hospital
    Hà Nội, Northern Vietnam, Vietnam
    Recruiting
  • Tam Anh General Hospital
    Hà Nội, Northern Vietnam, Vietnam
    Recruiting
  • Tam Anh TP. Ho Chi Minh General Hospital
    Ho Chi Minh City, Southern Vietnam, Vietnam
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.